Prevalere Is Acquired By ICON
NOV. 14, 2008- ICON, plc (NASDAQ: ICLR; ISIN:IE0005711209), today announced that it has acquired Prevalere Life Sciences, Inc., a wholly owned subsidiary of ORS Labs, Inc. Read the full release here.
See Us at These Upcoming Events
Scientists, consultants and business development professionals from Prevalere
Life Sciences, Inc. will be attending, presenting, or exhibiting at these upcoming
conferences. They will be available to provide company information or to discuss their areas of expertise, so please feel free to contact the attending Prevalere team member before or during these conferences to discuss an opportunity to meet. Click here for the full list.
Prevalere's Growth Sparks a Wave a New Hires
OCT. 6, 2008- Prevalere announces the recent addition of eight new employees to their scientific and administrative staff. Read the full release.
Download Dr. Mario Rocci's presentation "Confirmatory Re-Analysis of Incurred Samples - An Industry Perspective". This talk was presented at the 2007 AAPS National Biotechnology Conference in San Diego, CA
Prevalere CEO, Mario L. Rocci Jr., Ph.D., serves as Guest Editor of the themed issue of The AAPS Journal entitled, Bioanalytical Method Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays. Drs. Haughey and Jardieu of Prevalere Life Sciences, Inc. contributed to this issue of the Journal.
Prevalere Life Sciences, Inc. enters strategic partnership with BioPharma Services, Inc. a 50,000 sf Phase I/Bioequivalence Unit. This alliance enables Prevalere Life Sciences,Inc. to offer full support for Phase I and Bioequivalence studies.
For more information on BioPharma Services Inc. please visit http://www.biopharmaservices.ca
Prevalere adds Bioassay services to its suite of biotechnology services.
This service area uses a wide variety of cell culture techniques for your in vitro assay needs. These extensive capabilities permit assessment of the functional activity of your biologic in a timely and customized manner. For more information click here.
